FI971420A0 - Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä - Google Patents

Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä

Info

Publication number
FI971420A0
FI971420A0 FI971420A FI971420A FI971420A0 FI 971420 A0 FI971420 A0 FI 971420A0 FI 971420 A FI971420 A FI 971420A FI 971420 A FI971420 A FI 971420A FI 971420 A0 FI971420 A0 FI 971420A0
Authority
FI
Finland
Prior art keywords
kgf
procedure
treatment
diabetes mellitus
mammals
Prior art date
Application number
FI971420A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971420A7 (fi
FI971420L (fi
Inventor
Sharon Lea Aukerman
Glenn Frencis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI971420A7 publication Critical patent/FI971420A7/fi
Publication of FI971420A0 publication Critical patent/FI971420A0/fi
Publication of FI971420L publication Critical patent/FI971420L/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI971420A 1994-10-13 1995-10-12 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä FI971420L (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (3)

Publication Number Publication Date
FI971420A7 FI971420A7 (fi) 1997-04-04
FI971420A0 true FI971420A0 (fi) 1997-04-04
FI971420L FI971420L (fi) 1997-04-04

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971420A FI971420L (fi) 1994-10-13 1995-10-12 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
FI971536A FI120040B (fi) 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI971536A FI120040B (fi) 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja

Country Status (23)

Country Link
EP (2) EP0804479B1 (cs)
JP (2) JP4426646B2 (cs)
KR (1) KR100278597B1 (cs)
CN (1) CN1168678A (cs)
AT (2) ATE237633T1 (cs)
AU (1) AU3707795A (cs)
BG (2) BG101392A (cs)
BR (2) BR9509269A (cs)
CA (2) CA2202075C (cs)
CZ (3) CZ297328B6 (cs)
DE (2) DE69530403T2 (cs)
DK (2) DK0785948T3 (cs)
EE (2) EE9700225A (cs)
ES (2) ES2273338T3 (cs)
FI (2) FI971420L (cs)
HU (2) HU226168B1 (cs)
NO (2) NO971566L (cs)
NZ (2) NZ505502A (cs)
PL (2) PL320484A1 (cs)
PT (2) PT785948E (cs)
SI (2) SI0785948T1 (cs)
SK (2) SK284534B6 (cs)
WO (2) WO1996011950A1 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (en) 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2227527T3 (es) 1993-06-29 2005-04-01 Chiron Corp Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
EP1334981B1 (en) * 1994-10-13 2011-01-26 Swedish Orphan Biovitrum AB (publ) Method for purifying keratinocyte growth factors
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
DK0822943T3 (da) * 1995-04-27 1999-11-29 Cooperatie Cosun U A Inulinderivater
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
ATE263239T1 (de) * 1996-10-15 2004-04-15 Amgen Inc Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
RU2003125643A (ru) * 2001-02-06 2005-01-20 Мерк Патент ГмбХ (DE) Модифицированный фактор роста кератиноцита (kgf) с уменьшенной иммуногенностью
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
JP2005500390A (ja) * 2001-08-21 2005-01-06 カイロン コーポレイション Kgfポリペプチド組成物
PT1827483E (pt) 2004-12-15 2014-09-25 Swedish Orphan Biovitrum Ab Publ Formulações terapêuticas do fator de crescimento de queratinócitos
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd reg蛋白質
US5145225A (en) * 1988-07-27 1992-09-08 Muller George M Carpet stretcher
WO1990008771A1 (en) * 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 bFGFムテインおよびその製造法
FI954541A7 (fi) * 1993-03-26 1995-11-23 Amgen Inc Keratinosyyttikasvutekijän terapeuttisia käyttöjä
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
ES2227527T3 (es) * 1993-06-29 2005-04-01 Chiron Corp Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
EP0712314A1 (en) * 1993-08-02 1996-05-22 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
WO1996011949A3 (en) 1996-12-12
SI0785948T1 (en) 2003-08-31
SK284534B6 (sk) 2005-06-02
DE69535264T2 (de) 2007-02-01
HUT78050A (hu) 1999-07-28
NO318761B1 (no) 2005-05-02
HUT78058A (hu) 1999-07-28
SI0804479T1 (sl) 2006-12-31
CA2201940A1 (en) 1996-04-25
DK0785948T3 (da) 2003-08-04
EE03975B1 (et) 2003-02-17
ATE237633T1 (de) 2003-05-15
JPH10507193A (ja) 1998-07-14
CA2202075A1 (en) 1996-04-25
DE69535264D1 (de) 2006-11-23
HU226168B1 (en) 2008-05-28
NO971568D0 (no) 1997-04-04
ES2273338T3 (es) 2007-05-01
CZ297329B6 (cs) 2006-11-15
EP0804479B1 (en) 2006-10-11
EP0785948B1 (en) 2003-04-16
WO1996011949A2 (en) 1996-04-25
BG101392A (en) 1997-10-31
JP4216329B2 (ja) 2009-01-28
PL182888B1 (pl) 2002-03-29
PT785948E (pt) 2003-09-30
JP4426646B2 (ja) 2010-03-03
NO971566L (no) 1997-04-14
DK0804479T3 (da) 2007-01-29
BG63167B1 (bg) 2001-05-31
SK45597A3 (en) 1999-02-11
FI971420A7 (fi) 1997-04-04
EE9700225A (et) 1998-02-16
KR100278597B1 (ko) 2001-01-15
PT804479E (pt) 2007-02-28
BG101408A (bg) 1997-12-30
FI971536L (fi) 1997-06-09
BR9509269A (pt) 1997-12-23
FI120040B (fi) 2009-06-15
EP0785948A1 (en) 1997-07-30
FI971536A0 (fi) 1997-04-11
AU3707795A (en) 1996-05-06
CA2202075C (en) 2003-12-09
CZ105097A3 (cs) 1998-10-14
EP0804479A1 (en) 1997-11-05
FI971420L (fi) 1997-04-04
CN1168678A (zh) 1997-12-24
ES2196082T3 (es) 2003-12-16
NZ505502A (en) 2005-01-28
NO971566D0 (no) 1997-04-04
PL319784A1 (en) 1997-08-18
JPH10507080A (ja) 1998-07-14
NO971568L (no) 1997-06-12
WO1996011950A1 (en) 1996-04-25
NZ335109A (en) 2000-08-25
AU681546B2 (en) 1997-08-28
PL320484A1 (en) 1997-09-29
DE69530403T2 (de) 2003-10-30
CZ98197A3 (cs) 1998-11-11
ATE342278T1 (de) 2006-11-15
DE69530403D1 (de) 2003-05-22
CA2201940C (en) 2009-05-12
CZ297328B6 (cs) 2006-11-15
EE9700081A (et) 1997-10-15
AU3708395A (en) 1996-05-06
BR9509329A (pt) 1997-10-14
SK43197A3 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
AU2899889A (en) Novel method
AU5323396A (en) Methods of treating inflammation and compositions therefor
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69509318D1 (de) Hyperbarische Druckkammer für medizinische Hochdruck Behandlung mit keinen strukturellen Hindernissen
DE69113773D1 (de) Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers
UA28288A (uk) Спосіб лікування шизофренії
ATE315583T1 (de) Analoge des thymosin alpha 1
ATE318612T1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
AU3597695A (en) Improved method and composition for the treatment of ulcers
MY109685A (en) Method for treating hepatitis b carriers with minimal disease